On the AACR Annual Assembly 2026, preliminary outcomes from the BBOpCo medical examine evaluating first-line botensilimab (BOT) and balstilimab (BAL) in sufferers with microsatellite steady colorectal most cancers (MSS CRC) with out liver, bone, or mind metastases had been introduced by Nicholas C. DeVito, MD, Assistant Professor of Drugs within the Division of Medical Oncology at Duke College.
The examine, titled “Preliminary outcomes of first-line botensilimab (BOT) and balstilimab (BAL) optimization in MSS CRC with out liver, bone, or mind metastasis (BBOpCo)” (Summary CT184; NCT06268015), was introduced in the course of the Part I Medical Trials session on April 21, 2026.
Why This Examine Issues
Sufferers with metastatic MSS colorectal most cancers are usually handled with sequential chemotherapy regimens, usually experiencing illness development and extended toxicities over the course of remedy. Immunotherapy has traditionally proven restricted efficacy in MSS CRC, which is usually thought-about an immunologically “chilly” tumor.
This examine explored whether or not anatomical affected person choice — particularly excluding sufferers with liver, bone, or mind metastases — may establish a subgroup extra prone to profit from immune checkpoint blockade. The technique additionally aimed to delay or doubtlessly keep away from chemotherapy through the use of BOT and BAL within the first-line setting. The rationale was supported by prior information from a section I/II examine of BOT/BAL in pretreated MSS CRC sufferers, which achieved a 73% illness management price in sufferers with out liver metastases.
Examine Part 3 BATTMAN Trial in MSS or pMMR Metastatic Colorectal Most cancers on OncoDaily.
The BOT/BAL Mixture
Botensilimab (BOT) is an Fc-enhanced multifunctional anti–CTLA-4 antibody designed to activate each innate and adaptive anti-tumor immune responses. Its mechanism is geared toward bettering outcomes in immunologically “chilly” tumors, which usually present restricted responsiveness to standard checkpoint inhibitors. BOT enhances immune exercise by selling T-cell priming and enlargement, decreasing intratumoral regulatory T cells, activating myeloid cells, and supporting the event of long-term immune reminiscence.
Balstilimab (BAL) is a totally human monoclonal IgG4 antibody concentrating on PD-1. By blocking the interplay between PD-1 and its ligands PD-L1 and PD-L2, BAL restores T-cell operate and allows the immune system to acknowledge and assault tumor cells.
Collectively, BOT and BAL are designed to offer a complementary and doubtlessly synergistic immune response, combining early immune activation with sustained checkpoint inhibition. This twin mechanism could also be notably related in MSS colorectal most cancers, a setting the place normal immunotherapy approaches have traditionally proven restricted exercise.
Methodology and Affected person Inhabitants
This examine enrolled 15 beforehand untreated sufferers with stage IV MSS colorectal most cancers with out liver, bone, or mind metastases. Sufferers acquired botensilimab (75 mg each 6 weeks, as much as 4 doses) and balstilimab (240 mg each 2 weeks) as first-line remedy. Sufferers had a median age of fifty years, and 10 sufferers (66.7%) had been male. Websites of metastases included lymph nodes (20%), peritoneum (26.7%), lungs (33.3%), and different areas (20%). A median of three cycles of botensilimab had been administered.
Tumor assessments had been carried out each 6 weeks utilizing iRECIST standards. In instances of immune-confirmed progressive illness (iCPD), standard-of-care chemotherapy (FOLFOX plus bevacizumab or panitumumab) was added whereas persevering with balstilimab. Tumor biopsies had been collected at baseline and on the time of development to help exploratory biomarker analyses.
The first aims included security, feasibility, and illness management price (DCR) with BOT/BAL. Secondary endpoints included greatest total response to BOT/BAL alone (ORR1 by iRECIST) and following chemotherapy crossover (ORR2/DCR2 by RECIST), in addition to progression-free and total survival (PFS1, PFS2, OS). Exploratory analyses targeted on spatial tumor biology and immune microenvironment characterization from pre-treatment and development biopsies.
Key Findings
As of the info cutoff of January 5, 2026, one affected person (with a BRAF mutation) withdrew from remedy. At a median follow-up of 4.3 months (95% CI, 1.6–Not Estimable), 13 sufferers had been evaluable for efficacy and 14 for security.
The mix achieved a illness management price of 71%, together with one confirmed immune partial response (iPR) — in a affected person with lung metastases and a tumor mutational burden of 1 mut/Mb — and 4 instances of immune steady illness (iSD) at 24 weeks. 5 sufferers handled with BOT/BAL alone had been too early to evaluate on the time of information cutoff.
An vital medical consequence was the median freedom from crossover to chemotherapy of 8.7 months (95% CI, 6.2–NE). Among the many 4 sufferers who progressed and transitioned to standard-of-care chemotherapy at a median of 6.3 months from BOT/BAL initiation, three had been evaluable for response to chemotherapy by RECIST, demonstrating a 67% illness management price and confirming that subsequent chemotherapy efficiency was in step with expectations.
Security and Tolerability
The protection profile was in step with the mechanism of motion of checkpoint inhibitors. Amongst 14 sufferers evaluable for immune-related adversarial occasions (irAEs), 6 sufferers skilled Grade 1–2 occasions and seven skilled Grade 3 occasions. Importantly, no Grade 4 toxicities and no treatment-related deaths had been reported.
Grade 3 toxicity was primarily colitis, occurring in 5 of the 7 Grade 3 instances. Classes of irAEs of any grade skilled by multiple affected person included diarrhea/colitis, fatigue, rash, AST/ALT elevations, fever, hypothyroidism, and arthritis. Arthritis was successfully managed with naproxen or ibuprofen.
A proactive administration technique was applied to deal with the anticipated threat of immune-related colitis. Sufferers had been supplied with a brief course of prednisone to take dwelling previous to beginning remedy, enabling fast self-initiation of corticosteroids on the first indicators of colitis, adopted by infliximab inside 48 hours when wanted. This proactive method contributed to the absence of Grade 4 toxicities and treatment-related deaths.
Examine BOT/BAL and agenT-797 in PD-1 Refractory Gastroesophageal Most cancers on OncoDaily.
Translational and Biomarker Insights
Exploratory analyses utilizing multiplex immunohistochemistry revealed distinct organic variations between responders and non-responders. Sufferers who responded to remedy demonstrated elevated infiltration of cDC1s, whereas non-responders exhibited greater Spp1/CXCL9 macrophage ratios.
These findings present early perception into potential biomarkers of response and resistance and will inform future affected person choice methods.
Key Takeaways
This early-phase examine demonstrates that first-line botensilimab and balstilimab is possible and exhibits medical exercise in a rigorously chosen MSS colorectal most cancers inhabitants with out liver, bone, or mind metastases. The flexibility to delay chemotherapy, mixed with maintained responsiveness to subsequent remedy and rising biomarker insights, helps additional analysis of this method in bigger research.
Discover extra data on the official Agenus web site.
